Search Results - "Perez, Matthew C."

Management of acral lentiginous melanoma: current updates and future directions by Dugan, Michelle M, Perez, Matthew C, Karapetyan, Lilit, Zager, Jonathan S

“…Acral lentiginous melanoma is a rare subtype of melanoma generally associated with poor outcomes, even when diagnosed at an early stage. The tumor genetic…”
Get full text

Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1) by Perez, Matthew C, Zager, Jonathan S, Amatruda, Thomas, Conry, Robert, Ariyan, Charlotte, Desai, Anupam, Kirkwood, John M, Treichel, Sheryl, Cohan, David, Raskin, Leon

“…Talimogene laherparepvec (T-VEC) is an intralesional treatment for unresectable cutaneous, subcutaneous and nodal melanoma. COSMUS-1 was conducted to examine…”
Get full text

Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience by Perez, Matthew C., Miura, John T., Naqvi, Syeda Mahrukh Hussnain, Kim, Youngchul, Holstein, Amanda, Lee, Daniel, Sarnaik, Amod A., Zager, Jonathan S.

“…Background Talimogene laherparepvec (TVEC) is an oncolytic herpes virus used as intralesional therapy for patients with unresectable stage IIIB through IV…”
Get full text

Re-biopsy of partially sampled thin melanoma impacts sentinel lymph node sampling as well as surgical margins by Weitman, Evan S, Perez, Matthew C, Lee, Daniel, Kim, Youngchul, Fulp, William, Sondak, Vernon K, Sarnaik, Amod A, Gonzalez, Ricardo J, Cruse, Carl W, Messina, Jane L, Zager, Jonathan S

“…To assess the impact of re-biopsy on partially sampled melanoma (MIS), atypical melanocytic proliferation (AMP) and thin invasive melanoma. We retrospectively…”
Get full text

Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience by Louie, Raphael J., Perez, Matthew C., Jajja, Mohammad Raheel, Sun, James, Collichio, Frances, Delman, Keith A., Lowe, Michael, Sarnaik, Amod A., Zager, Jonathan S., Ollila, David W.

“…Talimogene laherparepvec (TVEC) is an FDA-approved oncolytic herpes virus used to treat unresectable stage IIIB to IV metastatic melanoma via intralesional…”
Get full text

Isolated hyperthermic perfusions for cutaneous melanoma in-transit metastasis of the limb and uveal melanoma metastasis to the liver by Huibers, Anne, DePalo, Danielle K., Perez, Matthew C., Zager, Jonathan S., Olofsson Bagge, Roger

“…Patients with cutaneous melanoma can develop in-transit metastases (ITM), most often localized to limbs. For patients with uveal melanoma that develop…”
Get full text

Clinical Characteristics and Special Considerations in the Management of Rare Melanoma Subtypes by Shannon, Adrienne B, Zager, Jonathan S, Perez, Matthew C

“…Rare histologic subtypes of melanoma, including acral, mucosal, uveal, and desmoplastic melanomas, only make up 5% of all diagnosed melanomas and are often…”
Get full text

Oncolytic intralesional therapy for metastatic melanoma by DePalo, Danielle K, Perez, Matthew C., Huibers, Anne, Olofsson Bagge, Roger, Zager, Jonathan S.

“…In-transit metastasis (ITM) develop in approximately 1 in 10 patients with melanoma and the disease course can vary widely. Surgical resection is the…”
Get full text

ASO Author Reflections: Resection Margins in Merkel Cell Carcinoma: Is a 1 cm Margin Wide Enough? by Perez, Matthew C., Zager, Jonathan S.

Get full text

Acral melanoma: clinical advances and hope for the future by Perez, Matthew C, Messina, Jane L, Karapetyan, Lilit, Neves, Rogerio I, Sondak, Vernon K

“…Acral melanoma is a rare subtype of melanoma with unique histologic and biologic characteristics. Given its relative rarity compared with nonacral cutaneous…”
Get full text

Management of Sentinel Lymph Node Metastasis in Merkel Cell Carcinoma: Completion Lymphadenectomy, Radiation, or Both? by Perez, Matthew C., Oliver, Daniel E., Weitman, Evan S., Boulware, David, Messina, Jane L., Torres-Roca, Javier, Cruse, C. Wayne, Gonzalez, Ricardo J., Sarnaik, Amod A., Sondak, Vernon K., Wuthrick, Evan J., Harrison, Louis B., Zager, Jonathan S.

“…Background Approximately 30% of patients with clinically localized Merkel cell carcinoma (MCC) show nodal involvement on sentinel lymph node biopsy (SLNB)…”
Get full text

Intralesional and Infusional Updates for Metastatic Melanoma by Dugan, Michelle M, Shannon, Adrienne B, DePalo, Danielle K, Perez, Matthew C, Zager, Jonathan S

“…Locoregionally advanced and metastatic melanoma represent a challenging clinical problem, but in the era of immune checkpoint blockade and intralesional and…”
Get full text

Resection Margins in Merkel Cell Carcinoma: Is a 1-cm Margin Wide Enough? by Perez, Matthew C., de Pinho, Felipe R., Holstein, Amanda, Oliver, Daniel E., Naqvi, Syeda M. H., Kim, Youngchul, Messina, Jane L., Burke, Erin, Gonzalez, Ricardo J., Sarnaik, Amod A., Cruse, C. Wayne, Wuthrick, Evan J., Harrison, Louis B., Sondak, Vernon K., Zager, Jonathan S.

“…Background Guidelines regarding specific resection margins for primary Merkel cell carcinoma (MCC) are not well established. The current National Comprehensive…”
Get full text

Clinical Correlates of Response to Anti-PD-1-based Therapy in Patients With Metastatic Melanoma by Davis, Elizabeth J, Perez, Matthew C, Ayoubi, Noura, Zhao, Shilin, Ye, Fei, Wang, Daniel Y, Sosman, Jeffrey A, Al-Rohil, Rami N, Eroglu, Zeynep, Johnson, Douglas B

“…Anti-PD-1 agents, alone or in combination with ipilimumab, produce durable responses in some melanoma patients. Tumor features that correlate with response are…”
Get full text

Bleeding From a Hepatic Artery-Portal Vein Fistula After Repair of a Stab Wound to the Liver by Perez, Matthew C, Kim, Steven C, Egunsola, Adekemi, Reitz, Alexandra, Archer-Arroyo, Krystal, Smith, Randi N, Williams, Keneeshia N, Udobi, Kahdi, Sola, Jr, Richard, Dente, Christopher J, Cristescu, Mircea M, Grant, April, Nguyen, Jonathan

Get more information

Hepatic Progression-free and Overall Survival After Regional Therapy to the Liver for Metastatic Melanoma by Abbott, Andrea M, Doepker, Matthew P, Kim, Youngchul, Perez, Matthew C, Gandle, Cassandra, Thomas, Kerry L, Choi, Junsung, Shridhar, Ravi, Zager, Jonathan S

“…Regional therapy for metastatic melanoma to the liver represents an alternative to systemic therapy. Hepatic progression-free survival (HPFS), progression-free…”
Get full text

Isolated Limb Infusion: A Single-Center Experience with Over 200 Infusions by O’Donoghue, Cristina, Perez, Matthew C., Mullinax, John E., Hardman, Danielle, Sileno, Sean, Naqvi, Syeda Mahrukh Hussnain, Kim, Youngchul, Gonzalez, Ricardo J., Zager, Jonathan S.

“…Background Isolated limb infusion (ILI) is a minimally invasive technique for delivering regional chemotherapy to an extremity for patients with locally…”
Get full text

Combination Atezolizumab, Cobimetinib, and Vemurafenib as a Treatment Option in BRAF V600 Mutation-Positive Melanoma: Patient Selection and Perspectives by Dugan, Michelle M, Perez, Matthew C, Karapetyan, Lilit, Zager, Jonathan S

“…The treatment landscape for advanced and metastatic melanoma has drastically changed in recent years, with the advent of novel therapeutic options such as…”
Get full text

Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: A single institution experience by Forster, Meghan R., Rashid, Omar M., Perez, Matthew C., Choi, Junsung, Chaudhry, Tariq, Zager, Jonathan S.

“…Background Patients with unresectable melanoma or sarcoma hepatic metastasis have a poor prognosis with few therapeutic options. Percutaneous hepatic perfusion…”
Get full text

Cutaneous Angiosarcoma: A Single-Institution Experience by Perez, Matthew C., Padhya, Tapan A., Messina, Jane L., Jackson, Ryan S., Gonzalez, Ricardo J., Bui, Marilyn M., Letson, G. Douglas, Cruse, C. W., Lavey, Robert S., Cheong, David, Forster, Meghan R., Fulp, William J., Sondak, Vernon K., Zager, Jonathan S.

“…Background Cutaneous angiosarcoma (CAS) is a rare, aggressive vascular sarcoma with a poor prognosis, historically associated with 5-year overall survival (OS)…”
Get full text